ORBIMED ADVISORS LLC 4
4 · Enliven Therapeutics, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Enliven Therapeutics (ELVN) OrbiMed Advisors (10% Owner) Sells Shares
What Happened
- OrbiMed Advisors LLC (reported as a 10% owner via affiliated funds) sold a total of 860,123 Enliven Therapeutics (ELVN) shares on June 22, 2026. The disposals consisted of 787,024 shares @ $45.38 ($35,715,149), 46,776 shares @ $45.00 ($2,104,920), 24,846 shares @ $45.38 ($1,127,511), and 1,477 shares @ $45.00 ($66,465), for aggregate proceeds of about $39,014,045. These were reported on a Form 4 filed June 24, 2026. These were sales (S) — disposals, not purchases.
Key Details
- Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (appears timely).
- Prices and amounts:
- 787,024 shares @ $45.38 — $35,715,149
- 46,776 shares @ $45.00 — $2,104,920
- 24,846 shares @ $45.38 — $1,127,511
- 1,477 shares @ $45.00 — $66,465
- Total shares sold: 860,123; Total proceeds: ~$39.0M
- Shares owned after transaction: not specified in the provided filing excerpt.
- Notable footnotes: sales were reported by OrbiMed Advisors through affiliated vehicles (OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP). OrbiMed Advisors is the managing member and may be deemed to have voting/investment power; reporting persons disclaim direct beneficial ownership except to the extent of any pecuniary interest.
- Filing timeliness: transaction reported two days after the trades; filing date indicates timely reporting under Section 16 deadlines.
Context
- This is institutional selling by a reported 10% owner (investment adviser/fund structure), not an individual executive or director. Such disposals can reflect portfolio rebalancing or liquidity needs and do not necessarily signal management sentiment about the company. As factual record: these were outright sales (code S) of existing shares, not option exercises, gifts, or awards.
Insider Transaction Report
Form 4Exit
ORBIMED ADVISORS LLC
10% Owner
Transactions
- Sale
Common Stock
[F1][F3]2026-06-22$45.38/sh−24,846$1,127,511→ 220,882 total(indirect: See Footnotes) - Sale
Common Stock
[F1][F3]2026-06-22$45.00/sh−1,477$66,465→ 219,405 total(indirect: See Footnotes) - Sale
Common Stock
[F2][F3]2026-06-22$45.38/sh−787,024$35,715,149→ 6,601,878 total(indirect: See Footnotes) - Sale
Common Stock
[F2][F3]2026-06-22$45.00/sh−46,776$2,104,920→ 6,555,102 total(indirect: See Footnotes)
Footnotes (3)
- [F1]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- [F3]This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.